Your browser doesn't support javascript.
loading
Health Benefits of Montmorency Tart Cherry Juice Supplementation in Adults with Mild to Moderate Ulcerative Colitis: A Protocol for a Placebo Randomized Controlled Trial.
Sinclair, Jonathan; Dillon, Stephanie; Allan, Robert; Brooks-Warburton, Johanne; Desai, Terun; Lawson, Charlotte; Bottoms, Lindsay.
Afiliação
  • Sinclair J; Research Centre for Applied Sport, Physical Activity and Performance, School of Sport & Health Sciences, Faculty of Allied Health and Wellbeing, University of Central Lancashire, Preston PR1 2HE, UK.
  • Dillon S; Research Centre for Applied Sport, Physical Activity and Performance, School of Sport & Health Sciences, Faculty of Allied Health and Wellbeing, University of Central Lancashire, Preston PR1 2HE, UK.
  • Allan R; Research Centre for Applied Sport, Physical Activity and Performance, School of Sport & Health Sciences, Faculty of Allied Health and Wellbeing, University of Central Lancashire, Preston PR1 2HE, UK.
  • Brooks-Warburton J; Gastroenterology Department, Lister Hospital, Stevenage SG1 4AB, UK.
  • Desai T; School of Life and Medical Sciences, University of Hertfordshire, Hatfield, AL10 9AB, UK.
  • Lawson C; School of Life and Medical Sciences, University of Hertfordshire, Hatfield, AL10 9AB, UK.
  • Bottoms L; Department of Comparative Biomedical Sciences, Royal Veterinary College, London NW1 0TU, UK.
Methods Protoc ; 6(5)2023 Aug 27.
Article em En | MEDLINE | ID: mdl-37736959
Ulcerative colitis, characterized by its relapsing and remissive nature, negatively affects perception, body image, and overall quality of life. The associated financial burden underscores the need for alternative treatment approaches with fewer side effects, alongside pharmaceutical interventions. Montmorency tart cherries, rich in anthocyanins, have emerged as a potential natural anti-inflammatory agent for ulcerative colitis. This manuscript outlines the study protocol for a randomized placebo-controlled trial investigating the effects of Montmorency tart cherry in individuals with ulcerative colitis. The trial aims to recruit 40 participants with mild to moderate disease activity randomly assign them to either a Montmorency tart cherry or placebo group. The intervention will span 6 weeks, with baseline and 6-week assessments. The primary outcome measure is the Inflammatory Bowel Disease Quality of Life Questionnaire. Secondary outcomes include other health-related questionnaires and biological indices. Statistical analysis will adhere to an intention-to-treat approach using linear mixed effect models. Ethical approval has been obtained from the University of Hertfordshire (cLMS/SF/UH/05240), and the trial has been registered as a clinical trial (NCT05486507). The trial findings will be disseminated through a peer-reviewed publication in a scientific journal.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies Idioma: En Revista: Methods Protoc Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies Idioma: En Revista: Methods Protoc Ano de publicação: 2023 Tipo de documento: Article